{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:04:42Z","timestamp":1777579482547,"version":"3.51.4"},"reference-count":65,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100004048","name":"Institute for Basic Sciences, Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran","doi-asserted-by":"publisher","award":["402012"],"award-info":[{"award-number":["402012"]}],"id":[{"id":"10.13039\/501100004048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The high incidence of Non-Alcoholic Fatty Liver Disease\n(NAFLD) as a hepatic component of metabolic syndrome is attributed to the ongoing\nrise in obesity rates. Given the beneficial effects of hydroxychloroquine (HCQ) on\nmetabolism, there is growing interest in combining it with fisetin (FSN), a natural product,\nto treat NAFLD more effectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The efficacy and safety of the combined therapy of FSN and HCQ in animal\nmodels of NAFLD were assessed, focusing on liver function, insulin sensitivity, oxidative\nstress, and inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>C57BL\/6J mice were fed either a standard chow diet or a high-\n-fat diet to induce NAFLD. FSN and HCQ were administered to the mice, and biochemical\nparameters related to glucose and lipid metabolism, as well as oxidative stress markers,\nwere measured in serum and liver tissue. Analyses included Oil Red O staining, mRNA\nlevels of key lipid metabolism molecules, and immunohistochemical assessments of\nmacrophage infiltration. Statistical analyses were performed using GraphPad Prism 9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>While the HCQ group exhibited some improvements in certain markers, it also\ndisplayed adverse effects. The FSN group, particularly the FSN + HCQ group, effectively\nreversed insulin sensitivity, glucose homeostasis, and NAFLD markers by modulating\nlipid metabolism and inflammation pathways. HCQ exacerbated oxidative stress, which\nwas mitigated by the effects of FSN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite concerns regarding the long-term side effects of HCQ, its combination\nwith FSN presents a promising approach for improving the management of NAFLD\nby reducing risks and enhancing outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673342421241126060049","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:51:28Z","timestamp":1739253088000},"page":"1467-1480","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health"],"prefix":"10.2174","volume":"33","author":[{"given":"Mahboobe","family":"Sattari","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghodratollah","family":"Panahi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Esmaeil","family":"Shahaboddin","sequence":"additional","affiliation":[{"name":"Institute for Basic Sciences, Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences, Kashan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohadese","family":"Sattari","sequence":"additional","affiliation":[{"name":"Institute for Basic Sciences, Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences, Kashan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siavash","family":"Amiri","sequence":"additional","affiliation":[{"name":"Institute for Basic Sciences, Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences, Kashan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Akhavan","family":"Taheri","sequence":"additional","affiliation":[{"name":"Anatomical Sciences Research Center, Institute forBasic Sciences, Kashan University of Medical Sciences, Kashan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Karimpour","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Amri","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"Younossi Z.M.","year":"2016","unstructured":"Younossi Z.M.; Koenig A.B.; Abdelatif D.; Fazel Y.; Henry L.; Wymer M.; Global epidemiology of nonalcoholic fatty liver disease-eta-analytic assessment of prevalence, incidence, and outcomes. Hepatology  2016,64(1),73-84","journal-title":"Hepatology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"Younossi Z.M.","year":"2019","unstructured":"Younossi Z.M.; Golabi P.; de Avila L.; Paik J.M.; Srishord M.; Fukui N.; Qiu Y.; Burns L.; Afendy A.; Nader F.; The global epidemiology of NAFLD and NASH in patients with Type 2 diabetes: A systematic review and meta-analysis. J Hepatol  2019,71(4),793-801","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","volume":"12","author":"Nassir F.","year":"2022","unstructured":"Nassir F.; NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules  2022,12(6),824","journal-title":"Biomolecules"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"Donnelly K.L.","year":"2005","unstructured":"Donnelly K.L.; Smith C.I.; Schwarzenberg S.J.; Jessurun J.; Boldt M.D.; Parks E.J.; Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest  2005,115(5),1343-1351","journal-title":"J Clin Invest"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","volume":"8","author":"Alves-Bezerra M.","year":"2017","unstructured":"Alves-Bezerra M.; Cohen D.E.; Triglyceride metabolism in the liver. Compr Physiol  2017,8(1),1-8","journal-title":"Compr Physiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.14218\/JCTH.2022.00067","volume":"10","author":"Clare K.","year":"2022","unstructured":"Clare K.; Dillon J.F.; Brennan P.N.; Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol  2022,10(5),939-946","journal-title":"J Clin Transl Hepatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.biopha.2021.111315","volume":"137","author":"Ahmed B.","year":"2021","unstructured":"Ahmed B.; Sultana R.; Greene M.W.; Adipose tissue and insulin resistance in obese. Biomed Pharmacother  2021,137,111315","journal-title":"Biomed Pharmacother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018814547204","volume":"5","author":"Hage M.P.","year":"2014","unstructured":"Hage M.P.; Al-Badri M.R.; Azar S.T.; A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab  2014,5(4),77-85","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=9","year":"2012","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury  2012","journal-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/1753-0407.13053","volume":"12","author":"Infante M.","year":"2020","unstructured":"Infante M.; Ricordi C.; Fabbri A.; Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. J Diabetes  2020,12(9),659-667","journal-title":"J Diabetes"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e3379","DOI":"10.1002\/dmrr.3379","volume":"37","author":"Stoian A.P.","year":"2021","unstructured":"Stoian A.P.; Catrinoiu D.; Rizzo M.; Ceriello A.; Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. Diabetes Metab Res Rev  2021,37(2),e3379","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/jpgm.JPGM_301_21","volume":"68","author":"Dutta D.","year":"2022","unstructured":"Dutta D.; Jindal R.; Mehta D.; Kumar M.; Sharma M.; Efficacy and safety of hydroxychloroquine for managing glycemia in Type-2 diabetes: A systematic review and meta-analysis. J Postgrad Med  2022,68(2),85-92","journal-title":"J Postgrad Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"106925","DOI":"10.1016\/j.phrs.2023.106925","volume":"196","author":"Wang L.","year":"2023","unstructured":"Wang L.; Yan Y.; Wu L.; Peng J.; Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development. Pharmacol Res  2023,196,106925","journal-title":"Pharmacol Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-319-41334-1_10","volume":"928","author":"Pal H.C.","year":"2016","unstructured":"Pal H.C.; Pearlman R.L.; Afaq F.; Fisetin and its role in chronic diseases. Adv Exp Med Biol  2016,928,213-244","journal-title":"Adv Exp Med Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fchem.2019.00697","volume":"7","author":"Grynkiewicz G.","year":"2019","unstructured":"Grynkiewicz G.; Demchuk O.M.; New perspectives for fisetin. Front Chem  2019,7,697","journal-title":"Front Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e21226","DOI":"10.1371\/journal.pone.0021226","volume":"6","author":"Maher P.","year":"2011","unstructured":"Maher P.; Dargusch R.; Ehren J.L.; Okada S.; Sharma K.; Schubert D.; Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One  2011,6(6),e21226","journal-title":"PLoS One"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/biom9090430","volume":"9","author":"AL-Ishaq R.K.","year":"2019","unstructured":"AL-Ishaq R.K.; Abotaleb M.; Kubatka P.; Kajo K.; B\u00fcsselberg D.; Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. Biomolecules  2019,9(9),430","journal-title":"Biomolecules"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejphar.2014.06.065","volume":"740","author":"Prasath G.S.","year":"2014","unstructured":"Prasath G.S.; Pillai S.I.; Subramanian S.P.; Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. Eur J Pharmacol  2014,740,248-254","journal-title":"Eur J Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"Pouwels S.","year":"2022","unstructured":"Pouwels S.; Sakran N.; Graham Y.; Leal A.; Pintar T.; Yang W.; Kassir R.; Singhal R.; Mahawar K.; Ramnarain D.; Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord  2022,22(1),63","journal-title":"BMC Endocr Disord"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3350\/cmh.2022.0070","volume":"28","author":"Ng C.H.","year":"2022","unstructured":"Ng C.H.; Huang D.Q.; Nguyen M.H.; Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clin Mol Hepatol  2022,28(4),790-801","journal-title":"Clin Mol Hepatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e15003","DOI":"10.1111\/1756-185X.15003","volume":"27","author":"Meng C.C.","year":"2024","unstructured":"Meng C.C.; Chen D.Y.; Chen Y.H.; Huang W.N.; Chen H.H.; Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, population-based cohort study. Int J Rheum Dis  2024,27(1),e15003","journal-title":"Int J Rheum Dis"},{"key":"ref=22","year":"2023","unstructured":"ACR. Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients.  Available From:  https:\/\/rheumatology.org\/press-releases\/study-finds-hcq-lowers-risk-of-nonalcoholic-fatty-liver-disease-in-ra-patients2023"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/2314808X.2023.2211832","volume":"10","author":"Hasan M.A.","year":"2023","unstructured":"Hasan M.A.; Ammar O.A.; Amer M.A.; Othman A.I.; Zigheber F.; El-Missiry M.A.; Hydroxychloroquine improves high-fat-diet-induced obesity and organ dysfunction via modulation of lipid level, oxidative stress, and inflammation. Egyptian J  Basic Appl Sci  2023,10(1),368-379","journal-title":"Egyptian J  Basic Appl Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s40495-020-00243-4","volume":"6","author":"Carvalho A.A.S.","year":"2020","unstructured":"Carvalho A.A.S.; Side effects of chloroquine and hydroxychloroquine on skeletal muscle: A narrative review. Curr Pharmacol Rep  2020,6(6),364-372","journal-title":"Curr Pharmacol Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"20l13476","DOI":"10.4088\/JCP.20l13476","volume":"81","author":"Gressier F.","year":"2020","unstructured":"Gressier F.; Verstuyft C.; Becquemont L.; Falissard B.; Corruble E.; Psychiatric side effects of chloroquine. J Clin Psychiatry  2020,81(5),20l13476","journal-title":"J Clin Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"m1432","DOI":"10.1136\/bmj.m1432","volume":"369","author":"Ferner R.E.","year":"2020","unstructured":"Ferner R.E.; Aronson J.K.; Chloroquine and hydroxychloroquine in COVID-19. BMJ  2020,369,m1432","journal-title":"BMJ"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-018-06847-9","volume":"33","author":"Blignaut M.","year":"2019","unstructured":"Blignaut M.; Espach Y.; van Vuuren M.; Dhanabalan K.; Huisamen B.; Revisiting the cardiotoxic effect of chloroquine. Cardiovasc Drugs Ther  2019,33(1),1-11","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","volume":"58","author":"Wasko M.C.M.","year":"2015","unstructured":"Wasko M.C.M.; McClure C.K.; Kelsey S.F.; Huber K.; Orchard T.; Toledo F.G.S.; Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: A randomised trial. Diabetologia  2015,58(10),2336-2343","journal-title":"Diabetologia"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"616075","DOI":"10.3389\/fneur.2020.616075","volume":"11","author":"Naddaf E.","year":"2021","unstructured":"Naddaf E.; Paul P.; AbouEzzeddine O.F.; Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes. Front Neurol  2021,11,616075","journal-title":"Front Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbrc.2020.02.110","volume":"525","author":"Fan Z.","year":"2020","unstructured":"Fan Z.; Xiao Q.; Impaired autophagic flux contributes to muscle atrophy in obesity by affecting muscle degradation and regeneration. Biochem Biophys Res Commun  2020,525(2),462-468","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2017.09.026","volume":"113","author":"Navarro C.D.C.","year":"2017","unstructured":"Navarro C.D.C.; Figueira T.R.; Francisco A.; Dal\u2019B\u00f3 G.A.; Ronchi J.A.; Rovani J.C.; Escanhoela C.A.F.; Oliveira H.C.F.; Castilho R.F.; Vercesi A.E.; Redox imbalance due to the loss of mitochondrial NAD(P)-transhydrogenase markedly aggravates high fat diet-induced fatty liver disease in mice. Free Radic Biol Med  2017,113,190-202","journal-title":"Free Radic Biol Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Chen Z.","year":"2020","unstructured":"Chen Z.; Tian R.; She Z.; Cai J.; Li H.; Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med  2020,152,116-141","journal-title":"Free Radic Biol Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"E543","DOI":"10.1152\/ajpendo.00342.2017","volume":"314","author":"Jin E.S.","year":"2018","unstructured":"Jin E.S.; Lee M.H.; Murphy R.E.; Malloy C.R.; Pentose phosphate pathway activity parallels lipogenesis but not antioxidant processes in rat liver. Am J Physiol Endocrinol Metab  2018,314(6),E543-E551","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1091\/mbc.e04-06-0477","volume":"15","author":"Kiffin R.","year":"2004","unstructured":"Kiffin R.; Christian C.; Knecht E.; Cuervo A.M.; Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell  2004,15(11),4829-4840","journal-title":"Mol Biol Cell"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e0173712","DOI":"10.1371\/journal.pone.0173712","volume":"12","author":"Qu X.","year":"2017","unstructured":"Qu X.; Sheng J.; Shen L.; Su J.; Xu Y.; Xie Q.; Wu Y.; Zhang X.; Sun L.; Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS. PLoS One  2017,12(3),e0173712","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e0184922","DOI":"10.1371\/journal.pone.0184922","volume":"12","author":"Circu M.","year":"2017","unstructured":"Circu M.; Cardelli J.; Barr M.; O\u2019Byrne K.; Mills G.; El-Osta H.; Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small- cell lung cancer cells. PLoS One  2017,12(9),e0184922","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/cells9051131","volume":"9","author":"Trivedi P.C.","year":"2020","unstructured":"Trivedi P.C.; Bartlett J.J.; Pulinilkunnil T.; Lysosomal biology and function: Modern view of cellular debris bin. Cells  2020,9(5),1131","journal-title":"Cells"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/ars.2014.5837","volume":"21","author":"Navarro-Yepes J.","year":"2014","unstructured":"Navarro-Yepes J.; Burns M.; Anandhan A.; Khalimonchuk O.; del Razo L.M.; Quintanilla-Vega B.; Pappa A.; Panayiotidis M.I.; Franco R.; Oxidative stress, redox signaling, and autophagy: Cell death versus survival. Antioxid Redox Signal  2014,21(1),66-85","journal-title":"Antioxid Redox Signal"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"104954","DOI":"10.1016\/j.jff.2022.104954","volume":"90","author":"Dai X.","year":"2022","unstructured":"Dai X.; Kuang Q.; Sun Y.; Xu M.; Zhu L.; Ge C.; Tan J.; Wang B.; Fisetin represses oxidative stress and mitochondrial dysfunction in NAFLD through suppressing GRP78-mediated endoplasmic reticulum (ER) stress. J Funct Foods  2022,90,104954","journal-title":"J Funct Foods"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.1021\/acs.jafc.8b02140","volume":"66","author":"Shi Y.S.","year":"2018","unstructured":"Shi Y.S.; Li C.B.; Li X.Y.; Wu J.; Li Y.; Fu X.; Zhang Y.; Hu W.Z.; Fisetin attenuates metabolic dysfunction in mice challenged with a high-fructose diet. J Agric Food Chem  2018,66(31),8291-8298","journal-title":"J Agric Food Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10571-015-0272-9","volume":"36","author":"Sandireddy R.","year":"2016","unstructured":"Sandireddy R.; Yerra V.G.; Komirishetti P.; Areti A.; Kumar A.; Fisetin imparts neuroprotection in experimental diabetic neuropathy by modulating Nrf2 and NF-\u03baB pathways. Cell Mol Neurobiol  2016,36(6),883-892","journal-title":"Cell Mol Neurobiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tifs.2017.10.003","volume":"70","author":"Naeimi A.F.","year":"2017","unstructured":"Naeimi A.F.; Alizadeh M.; Antioxidant properties of the flavonoid fisetin: An updated review of in vivo and in vitro studies. Trends Food Sci Technol  2017,70,34-44","journal-title":"Trends Food Sci Technol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"Schrezenmeier E.","year":"2020","unstructured":"Schrezenmeier E.; D\u00f6rner T.; Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol  2020,16(3),155-166","journal-title":"Nat Rev Rheumatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8162421","volume":"2017","author":"Alisi A.","year":"2017","unstructured":"Alisi A.; Carpino G.; Oliveira F.L.; Panera N.; Nobili V.; Gaudio E.; The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications. Mediators Inflamm  2017,2017,1-15","journal-title":"Mediators Inflamm"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1257596","DOI":"10.3389\/fimmu.2023.1257596","volume":"14","author":"Zhang W.","year":"2023","unstructured":"Zhang W.; Lang R.; Macrophage metabolism in nonalcoholic fatty liver disease. Front Immunol  2023,14,1257596","journal-title":"Front Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4582612","volume":"2020","author":"Richard S.A.","year":"2020","unstructured":"Richard S.A.; Kampo S.; Hechavarria M.E.; Sackey M.; Buunaaim A.D.B.; Kuugbee E.D.; Anabah T.W.; Elucidating the pivotal immunomodulatory and anti-inflammatory potentials of chloroquine and hydroxychloroquine. J Immunol Res  2020,2020,1-13","journal-title":"J Immunol Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/s41419-018-1136-2","volume":"9","author":"Dai C.","year":"2018","unstructured":"Dai C.; Xiao X.; Li D.; Tun S.; Wang Y.; Velkov T.; Tang S.; Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death Dis  2018,9(12),1164","journal-title":"Cell Death Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1089\/jmf.2019.4619","volume":"23","author":"Choi M.S.","year":"2020","unstructured":"Choi M.S.; Choi J.Y.; Kwon E.Y.; Fisetin alleviates hepatic and adipocyte fibrosis and insulin resistance in diet-induced obese mice. J Med Food  2020,23(10),1019-1032","journal-title":"J Med Food"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1039\/C8FO01615A","volume":"10","author":"Xu M.","year":"2019","unstructured":"Xu M.; Ge C.; Qin Y.; Gu T.; Lv J.; Wang S.; Ma Y.; Lou D.; Li Q.; Hu L.; Nie X.; Wang M.; Huang P.; Tan J.; Activated TNF-\u03b1\/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: Inhibition by dietary fisetin intervention. Food Funct  2019,10(3),1302-1316","journal-title":"Food Funct"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.3390\/ijms23095146","volume":"23","author":"Brankovi\u0107 M.","year":"2022","unstructured":"Brankovi\u0107 M.; Jovanovi\u0107 I.; Duki\u0107 M.; Radonji\u0107 T.; Opri\u0107 S.; Kla\u0161nja S.; Zdravkovi\u0107 M.; Lipotoxicity as the leading cause of non-alcoholic steatohepatitis. Int J Mol Sci  2022,23(9),5146","journal-title":"Int J Mol Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"12977","DOI":"10.1038\/ncomms12977","volume":"7","author":"Kubota N.","year":"2016","unstructured":"Kubota N.; Kubota T.; Kajiwara E.; Iwamura T.; Kumagai H.; Watanabe T.; Inoue M.; Takamoto I.; Sasako T.; Kumagai K.; Kohjima M.; Nakamuta M.; Moroi M.; Sugi K.; Noda T.; Terauchi Y.; Ueki K.; Kadowaki T.; Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun  2016,7(1),12977","journal-title":"Nat Commun"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"732929","DOI":"10.3389\/fphys.2021.732929","volume":"12","author":"Cunningham R.P.","year":"2021","unstructured":"Cunningham R.P.; Porat-Shliom N.; Liver zonation \u2013 revisiting old questions with new technologies. Front Physiol  2021,12,732929","journal-title":"Front Physiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e142241","DOI":"10.1172\/JCI142241","volume":"131","author":"Saltiel A.R.","year":"2021","unstructured":"Saltiel A.R.; Insulin signaling in health and disease. J Clin Invest  2021,131(1),e142241","journal-title":"J Clin Invest"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","volume":"14","author":"Sunny N.E.","year":"2011","unstructured":"Sunny N.E.; Parks E.J.; Browning J.D.; Burgess S.C.; Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab  2011,14(6),804-810","journal-title":"Cell Metab"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","volume":"28","author":"Sunny N.E.","year":"2017","unstructured":"Sunny N.E.; Bril F.; Cusi K.; Mitochondrial adaptation in nonalcoholic fatty liver disease: Novel mechanisms and treatment strategies. Trends Endocrinol Metab  2017,28(4),250-260","journal-title":"Trends Endocrinol Metab"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.23094","volume":"50","author":"Fujita K.","year":"2009","unstructured":"Fujita K.; Nozaki Y.; Wada K.; Yoneda M.; Fujimoto Y.; Fujitake M.; Endo H.; Takahashi H.; Inamori M.; Kobayashi N.; Kirikoshi H.; Kubota K.; Saito S.; Nakajima A.; Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology  2009,50(3),772-780","journal-title":"Hepatology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e24084","DOI":"10.1371\/journal.pone.0024084","volume":"6","author":"Serviddio G.","year":"2011","unstructured":"Serviddio G.; Giudetti A.M.; Bellanti F.; Priore P.; Rollo T.; Tamborra R.; Siculella L.; Vendemiale G.; Altomare E.; Gnoni G.V.; Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One  2011,6(9),e24084","journal-title":"PLoS One"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"109369","DOI":"10.1016\/j.jnutbio.2023.109369","volume":"118","author":"Goodarzi G.","year":"2023","unstructured":"Goodarzi G.; Tehrani S.S.; Panahi G.; Bahramzadeh A.; Meshkani R.; Combination therapy of metformin and p- coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high- fat diet obese C57BL\/6 mice. J Nutr Biochem  2023,118,109369","journal-title":"J Nutr Biochem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1194\/jlr.M081836","volume":"59","author":"Linden A.G.","year":"2018","unstructured":"Linden A.G.; Li S.; Choi H.Y.; Fang F.; Fukasawa M.; Uyeda K.; Hammer R.E.; Horton J.D.; Engelking L.J.; Liang G.; Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. J Lipid Res  2018,59(3),475-487","journal-title":"J Lipid Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/emm.2015.122","volume":"48","author":"Han H.S.","year":"2016","unstructured":"Han H.S.; Kang G.; Kim J.S.; Choi B.H.; Koo S.H.; Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med  2016,48(3),e218-e218","journal-title":"Exp Mol Med"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1159\/000493650","volume":"49","author":"Liou C. J.","year":"2018","unstructured":"Liou C. J.; Wei C. H.; Chen Y. L.; Cheng C. Y.; Wang C. L.; Huang W. C.; Fisetin protects against hepatic steatosis through regulation of the sirt1\/AMPK and fatty acid \u03b2-oxidation signaling pathway in high-fat diet-induced obese mice. Cell Physiol Biochem  2018,49(1),1870-1884","journal-title":"Cell Physiol Biochem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.foodchem.2013.01.060","volume":"139","author":"Cho Y.","year":"2013","unstructured":"Cho Y.; Chung J.H.; Do H.J.; Jeon H.J.; Jin T.; Shin M.J.; Effects of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague\u2013dawley rats fed on a high fat diet. Food Chem  2013,139(1-4),720-727","journal-title":"Food Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejphar.2011.07.021","volume":"668","author":"Prasath G.S.","year":"2011","unstructured":"Prasath G.S.; Subramanian S.P.; Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. Eur J Pharmacol  2011,668(3),492-496","journal-title":"Eur J Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fphar.2019.00855","volume":"10","author":"Qiao X.","year":"2019","unstructured":"Qiao X.; Zhou Z.C.; Niu R.; Su Y.T.; Sun Y.; Liu H.L.; Teng J.L.; Ye J.N.; Shi H.; Yang C.D.; Cheng X.B.; Hydroxychloroquine improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism. Front Pharmacol  2019,10,855","journal-title":"Front Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"175066","DOI":"10.1016\/j.ejphar.2022.175066","volume":"927","author":"Ashmawy A.I.","year":"2022","unstructured":"Ashmawy A.I.; El-Abhar H.S.; Abdallah D.M.; Ali M.A.; Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2\/STAT-3\/SOCS-3 pathway. Eur J Pharmacol  2022,927,175066","journal-title":"Eur J Pharmacol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673342421241126060049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239318\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673342421241126060049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:04:04Z","timestamp":1772435044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239318\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673342421241126060049","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}